Corneal Neovascularization: An Anti-VEGF Therapy Review

被引:304
作者
Chang, Jin-Hong [1 ]
Garg, Nitin K. [1 ]
Lunde, Elisa [1 ]
Han, Kyu-Yeon [1 ]
Jain, Sandeep [1 ]
Azar, Dimitri T. [1 ]
机构
[1] Univ Illinois, Dept Ophthalmol & Visual Sci, Illinois Eye & Ear Infirm, Chicago, IL 60612 USA
关键词
anti-VEGF therapy; corneal neovascularization; bevacizumab; ranibizumab; VEGF Trap; silencing RNA; ENDOTHELIAL GROWTH-FACTOR; HERPETIC STROMAL KERATITIS; FACTOR TRAP-EYE; SUBCONJUNCTIVAL BEVACIZUMAB INJECTION; DIABETIC MACULAR EDEMA; ACTIVATING-FACTOR PAF; TOPICAL BEVACIZUMAB; GRAFT-SURVIVAL; CHOROIDAL NEOVASCULARIZATION; OCULAR NEOVASCULARIZATION;
D O I
10.1016/j.survophthal.2012.01.007
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Corneal neovascularization is a serious condition that can lead to a profound decline in vision. The abnormal vessels block light, cause corneal scarring, compromise visual acuity, and may lead to inflammation and edema. Corneal neovascularization occurs when the balance between angiogenic and antiangiogenic factors is tipped toward angiogenic molecules. Vascular endothelial growth factor (VEGF), one of the most important mediators of angiogenesis, is upregulated during neovascularization. In fact, anti-VEGF agents have efficacy in the treatment of neovascular age-related macular degeneration, diabetic retinopathy, macular edema, neovascular glaucoma, and other neovascular diseases. These same agents have great potential for the treatment of corneal neovascularization. We review some of the most promising anti-VEGF therapies, including bevacizumab, VEGF trap, siRNA, and tyrosine kinase inhibitors. (Surv Ophthalmol 57:415-429, 2012. (C) 2012 Elsevier Inc. All rights reserved.)
引用
收藏
页码:415 / 429
页数:15
相关论文
共 142 条
[31]   The role of PDGF receptor inhibitors and PI3-kinase signaling in the pathogenesis of corneal neovascularization [J].
Dell, Susanne ;
Peters, Swaantje ;
Muether, Philipp ;
Kociok, Norbert ;
Joussen, Antonia M. .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2006, 47 (05) :1928-1937
[32]   Anatomy and physiology of the cornea [J].
DelMonte, Derek W. ;
Kim, Terry .
JOURNAL OF CATARACT AND REFRACTIVE SURGERY, 2011, 37 (03) :588-598
[33]   Topical bevacizumab therapy for corneal neovascularization [J].
DeStafeno, John J. ;
Kim, Terry .
ARCHIVES OF OPHTHALMOLOGY, 2007, 125 (06) :834-836
[34]   VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration [J].
Dixon, James A. ;
Oliver, Scott C. N. ;
Olson, Jeffrey L. ;
Mandava, Naresh .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (10) :1573-1580
[35]   An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular oedema [J].
Do, D. V. ;
Nguyen, Q. D. ;
Shah, S. M. ;
Browning, D. J. ;
Haller, J. A. ;
Chu, K. ;
Yang, K. ;
Cedarbaum, J. M. ;
Vitti, R. L. ;
Ingerman, A. ;
Campochiaro, P. A. .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2009, 93 (02) :144-149
[36]   The DA VINCI Study: Phase 2 Primary Results of VEGF Trap-Eye in Patients with Diabetic Macular Edema [J].
Do, Diana V. ;
Schmidt-Erfurth, Ursula ;
Gonzalez, Victor H. ;
Gordon, Carmelina M. ;
Tolentino, Michael ;
Berliner, Alyson J. ;
Vitti, Robert ;
Rueckert, Rene ;
Sandbrink, Rupert ;
Stein, David ;
Yang, Ke ;
Beckmann, Karola ;
Heier, Jeff S. .
OPHTHALMOLOGY, 2011, 118 (09) :1819-1826
[37]   Subconjunctival bevacizumab for corneal neovascularization [J].
Doctor, Priyanka P. ;
Bhat, Pooja V. ;
Foster, C. Stephen .
CORNEA, 2008, 27 (09) :992-995
[38]  
Dratviman-Storobinsky O, 2009, MOL VIS, V15, P2326
[39]   Killing the messenger: Short RNAs that silence gene expression [J].
Dykxhoorn, DM ;
Novina, CD ;
Sharp, PA .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2003, 4 (06) :457-467
[40]   Novel aspects of corneal angiogenic and lymphangiogenic privilege [J].
Ellenberg, David ;
Azar, Dimitri T. ;
Hallak, Joelle A. ;
Tobaigy, Faisal ;
Han, Kyu Yeon ;
Jain, Sandeep ;
Zhou, Zhongjun ;
Chang, Jin-Hong .
PROGRESS IN RETINAL AND EYE RESEARCH, 2010, 29 (03) :208-248